bladder cancer

News

The VOLGA trial shows that Imfinzi and Padcev could be a rival Keytruda+Padcev in perioperative treatment of muscle-invasive bladder cancer.

Oncology

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

News

The FDA has handed ImmunityBio a key label extension for bladder cancer therapy Anktiva, giving it a leg-up on rival drug Inlexzo from J&J.

News

AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.

News

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.

News

AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.